# HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

> **NCT04131413** · PHASE1 · RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 48 (estimated)

## Conditions studied

- Human Papillomavirus Type 16
- Cervical Intraepithelial Neoplasia Grade II
- Cervical Intraepithelial Neoplasia, Grade III

## Interventions

- **DRUG:** pNGVL4aCRTE6E7L2

## Key facts

- **NCT ID:** NCT04131413
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-14
- **Primary completion:** 2026-12-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04131413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04131413, "HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04131413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*